Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6901 鑽石投資. Please read: https://finlab.finance/en/setup?stock=6901

No install, open FinLab Studio

6901

鑽石投資 Other As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation.

2 active signals
Revenue ≥20% Foreign buy
This page refreshes daily after the close. Add 鑽石投資 to your watchlist to track signal changes on your next visit.
Valuation 37Quality 5Growth 98Momentum 41Chips 77

Is 鑽石投資 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 4th market percentile. Latest quarterly ROE ≈ -4.3%.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 5.0% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 407.5%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20%, Foreign net buying 5 straight days are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral +0.01
BearishNeutralBullish

Institutional rotation, concentration steady — neutral

  • Institutional rotation, concentration steady — neutral
  • 摩根大通 holds 1,859 lots
  • sellers have 740 lots left, ~410 sessions to clear

Window from 2026-01-17 · Price -9% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 摩根大通 has accumulated 1,859 lots since the start (sold 0%), still adding.
  • Main distributor 永豐金-桃園 peaked at 1,386 lots, has sold 40%, 836 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders -1.20pp, mid holders +10, retail +0.86pp — little change.
  • Foreign hedge-desk net short Net short -11,243 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
摩根大通永豐金-南投康和-嘉義兆豐-西螺凱基-斗六花旗環球
Distributing
永豐金-桃園港商野村亞東中國信託-永康台灣摩根士丹利凱基-新豐
Desks
own scale
凱基-台北富邦-敦南台新美林
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 摩根大通 +1,859
    sold 0%· still adding
  • 永豐金-南投 +1,609
    sold 0%· still adding
  • 康和-嘉義 +1,164
    sold 0%· still adding
  • 兆豐-西螺 +943
    sold 0%· still adding
  • 凱基-斗六 +428
    sold 0%· still adding
  • 花旗環球 +340
    sold 12%· still adding

Distributing

  • 永豐金-桃園 836 left
    sold 40%· paused recently
  • 港商野村 178 left
    sold 57%· paused recently
  • 亞東 210 left
    sold 38%· ~31 sessions to clear
  • 中國信託-永康 173 left
    sold 36%· paused recently
  • 台灣摩根士丹利 113 left
    sold 54%· ~8 sessions to clear
  • 凱基-新豐 27 left
    sold 89%· paused recently

Desks

  • 凱基-台北 -10,670
    day-trade · selling pressure
  • 富邦-敦南 -4,590
    unclassified
  • 台新 -1,057
    unclassified
  • 美林 -921
    hedge desk · will cover
Still selling 740 lots ~410 sessions to bottom at most
Recent buy/sell force +7,090 absorbed / -555 sold buyers slightly ahead
Hedge-desk net short -460 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 407.46%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

21 historical occurrences (since 2023-10-11)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 50%, Sample 20, Median -0.37%, Excess -4.3%, Beat mkt rate 25%；60-day: Win 11.1%, Sample 18, Median -9.66%, Excess -19%, Beat mkt rate 5.6%；120-day: Win 0%, Sample 17, Median -17.87%, Excess -39.49%, Beat mkt rate 0%

120 days after: historical avg -17.61%

20-day -2.25%
60-day -11.54%
120-day -17.61%
20-day
60-day
120-day
Win
50%
11.1%
0%
Sample
20
18
17
Median
-0.37%
-9.66%
-17.87%
Excess
-4.3%
-19%
-39.49%
Beat mkt rate
25%
5.6%
0%

Over 17 occurrences, 120-day forward avg declined 17.61%, lagged the market by 39.49 pts; win rate 0%.

Foreign net buying for 5 straight days

Active · now 5%

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

13 historical occurrences (since 2023-11-07)
Average forward return after Foreign net buying for 5 straight days。20-day: Win 33.3%, Sample 12, Median -3.55%, Excess -7.1%, Beat mkt rate 8.3%；60-day: Win 8.3%, Sample 12, Median -14.65%, Excess -20.23%, Beat mkt rate 0%；120-day: Win 0%, Sample 12, Median -22.74%, Excess -43.65%, Beat mkt rate 0%

120 days after: historical avg -26.8%

20-day -5.5%
60-day -15.79%
120-day -26.8%
20-day
60-day
120-day
Win
33.3%
8.3%
0%
Sample
12
12
12
Median
-3.55%
-14.65%
-22.74%
Excess
-7.1%
-20.23%
-43.65%
Beat mkt rate
8.3%
0%
0%

Over 12 occurrences, 120-day forward avg declined 26.8%, lagged the market by 43.65 pts; win rate 0%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

What does 鑽石投資 do? Company profile

其他；生技醫療創業投資 上市（臺灣證券交易所）

Overview

6901 對應證券為鑽石生技投資股份有限公司普通股，股票簡稱鑽石投資，為臺灣證券交易所上市公司，掛牌日期為2023-09-19。公司成立於2013-01-09，總部位於台北市中正區忠孝西路一段66號35樓，官方聯絡電話02-2703-1338。董事長為楊泮池，總經理兼發言人為吳友梅；英文簡稱為 DIAMOND BIOFUND，英文全名為 DIAMOND BIOFUND INC.。截至可查公司資料，實收資本額約新台幣85.286億元，已發行普通股約8.5286億股；公開資料顯示股本曾因員工認股權行使而小幅增加，故精確股數需以最新公開資訊觀測站公告為準。主要股東依公司官網2025-03-23股權結構揭露，包括中天生物科技股份有限公司持股25.30%、合一生技股份有限公司14.02%、蔡明興12.60%、蔡明忠12.60%、台新創業投資股份有限公司8.53%。創始股東包含中天生技、富邦金控、台新金控及潤泰集團。員工規模未在本次可查公開資料中明確確認。

Business

鑽石投資為永續型生技創投公司，核心業務是以自有資本與子公司投資生技醫療公司，聚焦新藥研發、細胞與基因治療、高階醫療器材、創新醫療服務、醫療通路、農業生技等早中期或具國際競爭力標的。其商業模式不同於製造業，營業收入主要反映已實現與未實現金融資產評價損益；上市、上櫃與興櫃投資標的依市場報價或成交均價評價，未上市標的則依市場法、資產法、特別股評價模型等進行評價。因此營收可能因投資組合股價、公允價值與處分損益大幅波動，甚至出現負營收。公司提供被投資企業資金外，也協助公司治理、智財布局、技術研發、臨床驗證、商業發展、募資與資本市場接軌。投資組合包括永笙-KY、醣基生醫、欣耀生醫、優億、Rejuvenate Bio、Bilayer、Theia（晶祈生技）、地天泰農業生技、Syncell（新析生技）、EyeYon、KCP Fund I 等。2025年法說資料顯示，2025年度營業收入為-10.7325億元，稅後淨損為-11.74732億元，每股虧損1.38元；2025年底現金、約當現金及一年內到期定存約27.565億元，投資項目約62.716億元，淨值約92.209億元，資產總額約93.587億元。

Outlook 2025–2028

2025至2028年展望主要取決於投資組合臨床、商業化、IPO與併購退出進度。公司法說資料指出，2026年第一季國際生技資本市場較偏好具商業化收入與技術創新的醫療科技公司，研發型生技公司若具臨床進展與併購題材仍具成長動能；台灣生技IPO仍是除半導體外的重要新興募資類別。投資組合動能包括：永笙-KY已於2026年4月30日上市，長新冠臍帶血細胞新藥取得美國FDA擴大使用計畫與收費標準，並規劃Ph3樞紐試驗及公庫配對保障服務；Syncell 2025年設備銷售19台、營收年增約302%，並與國際研究機構及藥廠客戶合作，未來兩年被公司列為較可能進入資本市場的標的之一；優億合成皂苷佐劑正在推進GMP量產、IA-C01疫苗臨床前及臨床規劃，也被公司列為較可能進入資本市場標的；EyeYon人工角膜產品在歐洲已上市銷售、2025年銷量較前一年翻倍，中國樞紐試驗完成收案且九成患者視力提升，美國已取得IDE核准；Theia人工視網膜第一例臨床有初步成果並規劃英國試驗；地天泰具廚餘處理與碳權申請題材。中長期若上述標的完成臨床里程碑、藥證、授權、上市或被國際大廠併購，將帶動鑽石投資淨值與處分收益；但風險包括生技研發失敗、臨床時程延誤、法規審查不確定、未上市標的評價下修、興櫃/上市櫃生技股價波動、全球資本市場風險偏好下降、募資環境轉弱，以及公司營收因公允價值變動而持續大幅波動。2027至2028年具體財務數字未見公司公開指引，本段屬基於公司法說與投資組合里程碑的研究推估。

Supply Chain

Upstream
  • 中天生物科技股份有限公司 4128 主要創始股東與2025年主要股東，亦為台股上櫃生技公司；提供早期資本、產業網絡及生技投資背景。
  • 富邦金融控股股份有限公司 2881 創始股東富邦金控，屬金融資本來源與股東網絡；公司官網列為創始股東之一。
  • 台新金融控股股份有限公司 2887 創始股東台新金控；台新創業投資為2025年主要股東之一，屬金融資本與投資網絡來源。
  • 潤泰集團 創始股東之一，為台灣企業集團而非單一台股代號；提供民間資本與產業網絡。
  • 中央研究院 研究機構，曾與鑽石投資合作衍生醣基生醫、新析生技等新創案源；非上市櫃公司。
  • 臺灣大學、清華大學、臺北醫學大學、國防醫學院、中興大學等學研單位 學研案源與技術轉譯來源；公司資料稱支持多所頂尖大學及研究機構衍生新創，非上市櫃公司。
Downstream
  • 永笙-KY 4178 被投資公司；細胞治療、臍帶血儲存與長新冠治療，2026年4月30日上市。
  • 醣基生醫 被投資公司；醣均相平台、抗癌疫苗、抗體新藥與醣基化ADC相關技術，台股興櫃公司。
  • 欣耀生醫 被投資公司；脂肪肝炎新藥與高肝安全性止痛藥，台股興櫃公司。
  • 優億股份有限公司 被投資公司；台灣未上市生技新創，核心為全合成皂苷疫苗佐劑，規劃臨床與資本市場進程。
  • Syncell（新析生技） 被投資公司；台灣未上市公司，開發細胞內可抓式顯微鏡與空間生物學高階儀器。
  • EyeYon Medical Ltd. 被投資公司；以色列未上市醫療器材公司，產品包括人工角膜EndoArt與治療型隱形眼鏡Hyper-CL。
  • Theia（晶祈生技／Theia Medical Technology） 被投資公司；未上市醫療科技公司，發展人工視網膜植入物。
  • 地天泰農業生技 被投資公司；未上市，發展有機廢棄物快速處理設備、酵素及潛在碳權應用。
  • Rejuvenate Bio 被投資公司；美國未上市公司，發展基因治療與心臟/代謝療法。
  • Bilayer Therapeutics 被投資公司；美國未上市公司，發展藥物傳遞與腸道疾病治療。

Competitors

  • 中天生物科技股份有限公司 4128 櫃買中心興櫃資料表曾列為鑽石投資評價採樣同業；雖主業為新藥開發，但亦有生技轉投資，與鑽石投資在生技投資資產與生技資本市場題材上相近。
  • 晟德大藥廠股份有限公司 4123 櫃買中心興櫃資料表列為採樣同業；主業為藥品與生技醫療投資，具生技投資控股色彩。
  • 台耀化學股份有限公司 4746 櫃買中心興櫃資料表列為採樣同業；主業為原料藥，並有生技醫療轉投資，作為相近評價參考。
  • 台杉投資管理顧問股份有限公司 國家級創投管理平台，非台股上市櫃公司；在台灣生技與科技創投案源上與鑽石投資有競合關係。
  • 國發基金及其他生技創投基金 非單一上市櫃公司；屬台灣生技新創募資與共同投資市場中的競爭或共同投資者。
Sources（17）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.